|Description||An orally bioavailable formulation of the ansamycin derivative 17-amino-17-demethoxygeldanamycin (17-AG) with potential antineoplastic activity. Oral Hsp90 inhibitor IPI-493 binds to and inhibits Hsp90, which may result the in growth inhibition in sensitive tumor cell populations.|
|Brife Description||IPI-493 is a potent and orally bioavailable Hsp90 inhibitor with Ki of 21 nM.|
|Synonyms||IPI493; IPI 493; NSC 255109; 17-Aminogeldanamycin; 17-Amino Geldanamycin; 17-Aminodemethoxygeldanamycin; 17-Amino-17-demethoxygeldanamycin|
|Storage||at -20°C 2 years|
Chlorobiocin is found to bind at a second ATP-binding site in the C-terminal domain of Hsp90, thus disrupting the dimerization of the Hsp90 complex.IC50 60μmol/...
KF25706 is derivative of radicicol, binds to the Hsp90 chaperone machinery, IC50 39nM.
C086 inhibits Hsp90 and BCR-ABL, resulting in decreased proliferation of tumor cells, including imatinib-resistant cells.
CH5138303 is a novel and potent Hsp90 inhibitor. CH5138303 showed high binding affinity for N-terminal Hsp90α (Kd=0.52nM) and strong in vitro cell growth inhibi...
NXD30001 inhibits Hsp90, potentially resulting in decreased tumor growth.
Retaspimycin(IPI 504) is a small-molecule inhibitor of heat shock protein 90 (Hsp90) with antiproliferative and antineoplastic activities.Retaspimycin binds to ...
MPC-3100 targets the N-terminal ATP-binding site of Hsp90 and blocks the activity of ATPase. In the Her2-luciferase degradation assay, MPC-3100 reduces this cli...
VER-50589 is a potent Hsp90 inhibitor with IC50 of 21 nM for Hsp90β.
Hsp980 is an orally bioavailable inhibitor of human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp980 binds to and inhibits the acti...
KF55823 is a derivative of radicicol, binds to the Hsp90 chaperone machinery.
PU-WS13 is a cell-permeable inhibitor of Grp94 (EC50 = 220 nM).It shows selectivity for Grp94 over the related Hsps Trap-1, Hsp90α, and Hsp90β. PU-WS13 blocks t...
Novobiocin is found to bind at a second ATP-binding site in the C-terminal domain of Hsp90, thus disrupting the interaction of both p23 and Hsp70 co-chaperones ...
Onalespib, also known as AT13387, is a synthetic, orally bioavailable, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic a...
Pochocin A is a patent Hsp90 inhibitor. IC50 90nM.
Herbimycin A is an ansamycin antibiotic that acts as a Src family kinase inhibitor. Binds to the SH domain and inhibits the activity of p60v-src and p210BCR-ABL...
NW-457 is a potent Hsp90 inhibitor with no detectable hepatocytotoxicity in vitro. It synergizes with ionizing irradiation to induce chromatin condensation, nuc...
TAS-116 is a inhibitor of Hsp90. It induces significant cytotoxicity in MM cells even in the presence of BMSCs, associates with downregulation of phospho-Akt an...
SST0116CL1 is a second-generation small molecule inhibitor of Hsp90, which leads to decreased expression of Hsp90 client proteins and reduced tumor cell prolife...
Luminespib, also known as AUY-922 (or NVP-AUY922), is a derivative of 4,5-diarylisoxazole and a third-generation heat shock protein 90 (Hsp90) inhibitor with po...
17-AAG is an orally bioavailable, small-molecule inhibitor of several receptor protein tyrosine kinases with potential antiangiogenic and antineoplastic activit...